No Data
No Data
Express News | Allogene Therapeutics To Present Pre-Clinical Data Highlighting Potential Of ALLO-329 At ACR Convergence
Gene Editing Therapeutics Market Report 2024, Featuring Profiles of Key Players Allogene Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Sangamo Therapeutics and Vertex Pharmaceuticals - ResearchAndMarkets.com
H.C. Wainwright Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $9
CCORF Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $14
Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript
Express News | Citigroup Maintains Buy on Allogene Therapeutics, Raises Price Target to $8
No Data
No Data